Search
Friday Aug 8 2008
All times are London time
All times are London time
The 6am cut - Alphaville by email
Most Popular Posts
- Further Reading
- Further Reading
- The credit crunch, crunched: Authers and Murphy on a screen near you
- Further Reading
- Pink Picks
- Icahn: Well, maybe I can't -- at least, not on my own....
- Snap News
- Pink Picks
- Pink Picks
- Snap News
- Show more...
- Show less...
Blogs we're reading
- 1440 Wall Street
- Abnormal Returns
- Alea
- All About Alpha
- Arbitrage View
- Bespoke Investment Group
- Big Picture
- Brad Setser: Follow the money
- Calculated Risk
- Capital Chronicle
- Capitalist Resistance
- Crossing Wall Street
- Deal Journal
- Dealbook
- Dealbreaker
- Deus Ex Macchiato
- Felix Salmon
- Financial Armageddon
- Financial Crookery
- Fintag
- Free Exchange
- Infectious Greed
- Information Arbritrage
- Intelligent Mergers
- Interactive Investor
- Jeff Matthews
- Marketbeat
- Naked Capitalism
- Naked Shorts
- Nouriel Roubini
- Practical Risk Management
- Random Roger
- Reuters DealZone
- Robert Peston
- Short Stories
- Sudden Debt
- The Aleph blog
- The Epicurean Dealmaker
- The Oil Drum
- The price of everything
- Ultimi Barbarorum
- Wallstrip
Classified Jobs
- Divisional Financial Controller
- Recruiter: TRL
- Corporate Finance Controller / Corporate Finance Analyst
- Recruiter: Travelodge
- Acquisitions Analyst / Corporate Finance Analyst
- Recruiter: Travelodge
- Process & Control Development Manager
- Recruiter: Norwich Union
- Head of Project Finance
- Recruiter: Global Investment Bank
- Associate Director, Project Finance
- Recruiter: Global Investment Bank
- Collateral Frameworks and Registries Senior Advisor
- Recruiter: FIAS, The World Bank Group
- Group Finance Manager
- Recruiter: Marks & Spencer
Site Navigation
Principal content
aig barclays BSNL carlyle china citi cvc fortis fortress friends provident jc flowers Lombard Lonmin M&G merrill lynch Moodys Ping An Insurance sprint nextel ubs xstrata
Australia’s Sigma eyes bid for Symbion
Australia’s Sigma Pharmaceuticals on Thursday emerged as a potential bidder for the pharmacy services and consumer businesses of domestic rival Symbion Health, potentially creating an obstacle to an agreed A$2.86bn bid for Symbion by Healthscope. Healthscope and its private equity partners, Ironbridge Capital and Archer Capital, have already received board approval for their Symbion bid in a deal that would create Australia’s largest hospital and diagnostics group. Under that deal Symbion would be split up between Healthscope and the private equity firms, which would take the pharmacy and consumer businesses.
- Advertise with the FT
- Press enquiries
- Student offers
- FT Conferences
- FT Research Centre
- Corporate subscriptions
- FT Group
- Partner sites: Chinese FT.com
- Les Echos
- FT Deutschland
- Expansion
- © Copyright The Financial Times Ltd 2007. "FT" and "Financial Times" are trademarks of The Financial Times Ltd. Privacy policy
- Terms
Comments
This post is closed to comments.